Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors.
Oudijk L, Gaal J, Korpershoek E, van Nederveen FH, Kelly L, Schiavon G, Verweij J, Mathijssen RH, den Bakker MA, Oldenburg RA, van Loon RL, O'Sullivan MJ, de Krijger RR, Dinjens WN. Oudijk L, et al. Among authors: den bakker ma. Mod Pathol. 2013 Mar;26(3):456-63. doi: 10.1038/modpathol.2012.186. Epub 2012 Nov 23. Mod Pathol. 2013. PMID: 23174939 Free article.
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K. Burger H, et al. Among authors: den bakker ma. Cancer Biol Ther. 2005 Nov;4(11):1270-4. doi: 10.4161/cbt.4.11.2253. Epub 2005 Nov 18. Cancer Biol Ther. 2005. PMID: 16294026 Free article.
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C. Mearadji A, et al. Among authors: den bakker ma. Anticancer Drugs. 2008 Jul;19(6):607-12. doi: 10.1097/CAD.0b013e32830138f9. Anticancer Drugs. 2008. PMID: 18525320
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M. Hollestelle A, et al. Among authors: den bakker ma. Breast Cancer Res Treat. 2010 May;121(1):53-64. doi: 10.1007/s10549-009-0460-8. Epub 2009 Jul 11. Breast Cancer Res Treat. 2010. PMID: 19593635
TP53 mutation analysis of malignant peripheral nerve sheath tumors.
Verdijk RM, den Bakker MA, Dubbink HJ, Hop WC, Dinjens WN, Kros JM. Verdijk RM, et al. Among authors: den bakker ma. J Neuropathol Exp Neurol. 2010 Jan;69(1):16-26. doi: 10.1097/NEN.0b013e3181c55d55. J Neuropathol Exp Neurol. 2010. PMID: 20010306
145 results